REGN LONG2 CASES POSSIBLE..as usual UP or DOWN..
Short term Long for REGN .. tgt 325-331
If dumps then we may touch 240 and 215
Currently long at 310. Stop 297.
REGN trade ideas
$REGN Difficult to be bullish on Regeneron Pharma Inc. Regeneron is just another victim of the outflows from healthcare, there is nothing positive to cling to on the chart. As earnings approaches price action can only indicate that more selling is imminent, short for now and look for long on test of support or trend line.
FDA approves Dupixent® (dupilumab) for moderate-to-severe atopicREGN: Regeneron Pharmaceuticals, Inc.
2019-03-11 15:44:00
FDA Approves Dupixent® (dupilumab) for Moderate-to-severe Atopic Dermatitis in Adolescents - PR Newswire
$REGN Potential problem potential mini H&S developing on the daily near top of trend line. MACD suggest not enough strength to break TL. Watching for a break of the neckline.
$REGN Short swing Previous channel resistance, i can't help but think this will retest 400 and the 50 ema on daily.
Short REGN (Once 340 confirms a break)Watch very congested area at 340, short it once that is broken.
Short REGN from 365 (Potential bounce)to 183Potential bounce to 365 area before falling again, target price at 183
Really beautiful buying setup - REGNWill wait patiently for REGN to get into the buying box -- expect it to arrive last august
[REGN] phase 1 -> phase 2The price is above 30MM, the slope of 30MM is positive!
If the price breaks the resistant, It will be in phase 2.
But if you take risks, maybe you should buy!
REGN Short Play - Negative Divergence and Fib resistanceREGN hitting some resistance here and negative divergence on the RSI.
Inside bar with closed with a doji today.
$REGN 50d/200d Golden Cross$REGN Regeneron Pharma - 50d/200d ema Golden Cross on the daily chart last week after a solid earnings report in early August. Assuming bullish trend line holds, expecting continued gains over the next couple months.
Near term target - $391 (gap fill)
Medium term target - $420
FDA Approves EYLEA® (aflibercept) Injection sBLAREGN: Regeneron Pharmaceuticals, Inc.
2018-08-17 07:00:00
FDA Approves EYLEA® (aflibercept) Injection sBLA in Wet Age-related Macular Degeneration
Regeneron and Teva Announce Positive Topline Phase 3TEVA: Teva Pharmaceutical Industries Ltd.
2018-08-16 07:00:00
Regeneron and Teva Announce Positive Topline Phase 3 Fasinumab Results in Patients with Chronic Pain from Osteoarthritis of the Knee or Hip
REGN- Slowly Bleeding to Death.....CURE TO COMETaking a quick look at the chart and analyzing volume, one can easily see the turnaround is soon to come. Look for a consistent price turnaround in the month of July (2018). The confirmed turnaround should occur early-mid August (2018). What do I know right???
REGN: CHANGE IN TRENDIt seems the stock is changing the trend and may have bottomed out.
Please ignore my previous post as targets were not correct.
